Presentation is loading. Please wait.

Presentation is loading. Please wait.

Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18.

Published byHilary Todd Modified over 9 years ago

Similar presentations

Presentation on theme: "Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18."— Presentation transcript:

1 Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

2 Relationship Between Rates of Elevated Liver Enzymes and % LDL-C Reduction Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

3 Relationship Between Rates of Rhabdomyolysis and % LDL-C Reduction Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

4 Rate of Elevated Liver Enzymes by Statin Dose Category Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

5 Rate of Elevated Liver Enzymes by Lovastatin Dose Category Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

6 Rate of Elevated Liver Enzymes by Simvastatin Dose Category Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

7 Rate of Elevated Liver Enzymes by Atorvastatin Dose Category Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

8 Characteristics of Large Prospective Randomized Controlled Statin Trials in Which Incident Cancer Rates Were Reported, and Used for the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

9 Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and % LDL-C Reduction Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

10 Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Absolute LDL-C Reduct Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

11 Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Achieved LDL-C Level Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

12 Rate of Newly Diagnosed Cancer by Statin Dose Category Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

13 References Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18

Download ppt "Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18."

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165: 2264-2271.

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer CCOP Investigators’
P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,

P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,
Treat Everyone to an LDL-C of 70mg/dl? Daniel Edmundowicz, MS, MD, FACC Associate Professor Of Medicine Director, Preventive Cardiology UPMC Cardiovascular.

Treat Everyone to an LDL-C of 70mg/dl? Daniel Edmundowicz, MS, MD, FACC Associate Professor Of Medicine Director, Preventive Cardiology UPMC Cardiovascular.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin 20-40 mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Trial Identification, Inclusion, and Exclusion Krista M. Dale et al, JAMA. 2006; 295: 74-80.

Trial Identification, Inclusion, and Exclusion Krista M. Dale et al, JAMA. 2006; 295:
Simvastatin Increases HDL-C and Apolipoprotein A-1 Levels Significantly More Than Atorvastatin John P. Kastelein, Evan A. Stein, Michael A. Davidson, John.

Simvastatin Increases HDL-C and Apolipoprotein A-1 Levels Significantly More Than Atorvastatin John P. Kastelein, Evan A. Stein, Michael A. Davidson, John.
Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.

CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Role of Rosuvastatin in the Treatment of Dyslipidemia

Role of Rosuvastatin in the Treatment of Dyslipidemia
VOYAGER An indiVidual patient data meta- analysis Of statin therapY in At risk Groups: Effects of Rosuvastatin, atorvastatin and simvastatin Please see.

VOYAGER An indiVidual patient data meta- analysis Of statin therapY in At risk Groups: Effects of Rosuvastatin, atorvastatin and simvastatin Please see.
VBWG HPS. Lancet. 2003;361:2005-16. Gæde P et al. N Engl J Med. 2003;348:383-93. Recent statin trials: Reduction in primary outcome in patients with diabetes.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
Michal Vrablík Centre for Preventive Cardiology 3 rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague Czech Republic.

Michal Vrablík Centre for Preventive Cardiology 3 rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague Czech Republic.

Similar presentations

Ads by Google